Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Oncolytics Biotech Inc. has filed a Follow-on Equity Offerin

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Aug 06, 2024 12:46am

129 Views

Post# 36165380

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Oncolytics Biotech Inc. has filed a Follow-on Equity Offerin

I can't think of anything positive of this $50 million announcement. This highlights the fact they are unable to attract a partner and further dilution of the stock is never beneficial to shareholders. At the current price we will be over 100 million shares again. The biggest negative being unable to secure a partner.

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest